Sonnet BioTherapeutics Reports Data From Phase 1b/2a Clinical Trial Of SON-080 In Chemotherapy-Induced Peripheral Neuropathy That Support Advancement Into Phase 2 Study
$SONN
Biotechnology: Pharmaceutical Preparations
Health Care
- Data indicates that SON-080 was well-tolerated at both doses, with no evidence of a pro-inflammatory cytokine response
- Pain and quality of life survey results suggest the potential for rapid improvement of peripheral neuropathy symptoms and post-dosing durability with both doses, compared to placebo controls
- Sonnet intends to seek a partnership to support initiation of a Phase 2 clinical trial of SON-080 in Diabetic Peripheral Neuropathy (DPN), a mechanistically synergistic and larger, high-value indication with unmet medical need
- Management highlights data findings in a Virtual Investor "What This Means" segment